Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Soleno Therapeutics (SLNO) Debt to Equity (2025)

Soleno Therapeutics (SLNO) has disclosed Debt to Equity for 4 consecutive years, with $0.11 as the latest value for Q4 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $0.11 in Q4 2025 year-over-year; TTM through Dec 2025 was $0.11, a N/A change, with the full-year FY2025 number at $0.11, changed N/A from a year prior.
  • Debt to Equity was $0.11 for Q4 2025 at Soleno Therapeutics, up from $0.1 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.21 in Q1 2025 to a low of $0.1 in Q3 2025.